Bank Of America Corp Nu Cana PLC Transaction History

Bank Of America Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.66 - $27.41 $3,652 - $151,686	-5,534 Reduced 31.97%	11,776 $7,000
Q3 2022 Nov 14, 2022	BUY	$0.62 - $26.13 $10,732 - $452,310	17,310 New	17,310 $18,000
Q1 2022 May 16, 2022	SELL	$0.74 - $3.27 $27,510 - $121,565	-37,176 Reduced 49.08%	38,570 $39,000
Q4 2021 Feb 08, 2022	BUY	$2.02 - $2.9 $70,839 - $101,700	35,069 Added 86.21%	75,746 $180,000
Q3 2021 Nov 15, 2021	BUY	$1.95 - $2.85 $72,992 - $106,681	37,432 Added 1153.53%	40,677 $105,000
Q2 2021 Sep 13, 2021	BUY	$2.7 - $5.04 $8,761 - $16,354	3,245 New	3,245 $9,000

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $66.3M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.